Zioła peruwiańskie w Europie

• Autorzy: Paradowska K. , Wawer I.

Warianty tytułu

EN

Peruvian herbs in Europe

• Języki publikacji: PL

Abstrakty

PL

Przyroda Ameryki Południowej, w tym Peru, to prawdziwa naturalna apteka; uważa się, że ponad 80% rosnących tu roślin ma właściwości lecznicze. Rejonem Andów i dorzeczem Amazonki interesują się zarówno firmy farmaceutyczne jak i ośrodki akademickie na całym świecie. Kilka roślin tego regionu zdobyło już rozgłos w Europie, należą do nich: Cat’s claw (Uncaria tomentosa), Maca (Lepidium meyenii) czy Dragon’s blood (Croton lechleri). Każda z nich ma bardzo długą tradycję stosowania przez Indian w Ameryce Południowej. Jednak popularyzacja tych roślin jako surowców farmaceutycznych czy też roślin uzupełniających dietę mieszkańców Europy wymaga przeprowadzenia badań fitochemicznych, biologicznych oraz farmakologicznych.

EN

Nature of South America, including Peru, is a real natural pharmacy; it is believed that over 80% of plants growing here have medicinal properties. Region of the Andes and the Amazon basin are exceptionally interesting to pharmaceutical companies and academic institutions worldwide. A few plants from this region, such as: Cat’s claw (Uncaria tomentosa), Maca (Lepidium meyenii) and Dragon’s blood (Croton lechleri) have already gained a reputation in Europe. Every one of them has a long tradition of use by Indians in South America. However, the popularization of these plants as pharmaceutical raw materials or products complementing the diet of European citizens requires phytochemical, biological and pharmacological studies.

Słowa kluczowe

PL

Peru; rosliny lecznicze; wlasciwosci lecznicze; surowce farmaceutyczne; substancje biologicznie czynne; fitochemia; medycyna ludowa; Phyllanthus niruri; Annona muricata; flaszowiec miekkociernisty; guanabana zob.flaszowiec miekkociernisty; graviola zob.flaszowiec miekkociernisty; Euterpe oleracea; euterpa warzywna; Croton lechleri; smocza krew; sangro de drago zob.smocza krew; Tabebuia serratifolia; Banisteriopsis caapi

• Wydawca: -
• Czasopismo: Herbalism
• Rocznik: 2015
• Numer: 1
• Opis fizyczny: s.20-38,fot.,bibliogr.

Twórcy

autor

Paradowska K.

• Zakład Chemii Fizycznej, Warszawski Uniwersytet Medyczny, ul.Banacha 1, 02-097 Warszawa

autor

Wawer I.

• Zakład Chemii Fizycznej, Warszawski Uniwersytet Medyczny, ul.Banacha 1, 02-097 Warszawa

Bibliografia

• [1] Gonzales G.F., i wsp., Medicinal plants from Peru: a review of plants as potential agents against cancer, Anti-cancer Agents in Medicinal Chemistry 2006, 6(5), s. 429–444.
• [2] Żurowska K., Ziołolecznictwo amazońskie i andyjskie, Tower Oress, Gdańsk, 2001.
• [3] Paradowska K., i wsp., 13C, 15N CPMAS NMR and CIAO DFT calculations of stereoisomeric oxindole alkaloids from Cat’s claw (Uncaria tomentosa), Solid State NMR, 2008, 34, s. 202–209.
• [4] Brandão M.G., i wsp., Survey of medicinal plants used as antimalarials in the Amazon. Journal of Ethnopharmacology 1992, 36(2), s. 175–182.
• [5] Ma X., i wsp., The genus Desmodium (Fabaceae) –traditional uses in Chinese medicine, phytochemistry and pharmacology, Journal of Ethnopharmacology, 2011, 138(2), s. 314–332.
• [6] Addy M.E. i wsp., Dose-response effects of Desmodium adscendens aqueous extract on histamine response, content and anaphylactic reactions in the guinea pig, Journal of Ethnopharmacology, 1996, 18(1), s. 13–20.
• [7] Addy M.E. i wsp., An extract of Desmodium adscendens activates cyclooxygenase and increases prostaglandin synthesis by ram seminal vesicle microsomes, Phytotherapy Research, 1995, 9(4), s. 287–93.
• [8] Addy M.E. i wsp., Some secondary plant metabolites in Desmodium adscendens and their effects on arachidonic acid metabolism, Prostaglandins Leukotrienes and Essential Fatty Acids, 1992, 47(1), s. 85–91.
• [9] Addy M.E. i wsp., Effect of Desmodium adscendens fraction 3 on contractions of respiratory smooth muscle, Journal of Ethnopharmacology, 1990, 29(3), s. 325–335.
• [10] Addy M.E. i wsp., Several chromatographically distinct fractions of Desmodium adscendens inhibit smooth muscle contractions, International Journal of Crude Drug Research, 1989, 27(2), s. 81–91.
• [11] Addy M.E. i wsp., Effect of Desmodium adscendens fractions on antigen- and arachidonic acid-induced contractions of guinea pig airways, Canadian Journal Physiology and Pharmacology, 1987, 66(6), s. 820–825.
• [12] Addy M.E. i wsp., Dose-response effect of one subfraction of Desmodium adscendens aqueous extract on antigen- and arachidonic acid-induced contractions of guinea pig airways, Phytotheraphy. Research, 1987, 1(4), s. 180–186.
• [13] N’gouemo P. i wsp., Effects of an ethanolic extract of Desmodium adscendens on central nervous system in rodents, Journal of Ethnopharmacology, 1996, 52(2), s. 77–83.
• [14 ]Barreto G.S., Effect of butanolic fraction of Desmodium adscendens on the anococcygeus of the rat, Brazilian Journal of Biology, 2002, 62(2), s. 223–230.
• [15] Muanda F.N. i wsp., Chemical Composition and, Cellular Evaluation of the Antioxidant Activity of Desmodium adscendens Leaves, Evidence-Based Complementary and Alternative Medicine, 2011, 2011, s. 1–9.
• [16] Catapan E. i wsp., Pharmacological activity and chemical compositions of callus culture extracts from selected species of Phyllanthus, Pharmazie, 2000, 55 (12), s. 945–946.
• [17] Boim M.A. i wsp., Phyllanthus niruri as a promising alternative treatment for nephrolithiasis, International Brazilian Journal of Urology, 2010, 36, s. 657–64.
• [18] Lannuzel A., i wsp., Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? Journal of Neural Transmission. Supplementa, 2006, 70, s. 153–157.
• [19] Champy P., i wsp., MALDI-TOF MS profiling of annonaceous acetogenins in Annona muricata products for human consumption, Molecules, 2009, 14(12), s. 5235–5246.
• [20] Champy P. i wsp., Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe, Movement Disorders, 2005, 20(12), s. 1629–1633.
• [21] Adewole S.O., i wsp., Protective effects of Annona muricata Linn. (Annonaceae) leaf queous extract on serum lipid profiles and oxidative stress in hepatocytes of streptozotocin-treated diabetic rats, African Journal of Traditional Complementary Alternative Medicines, 2008, 6(1), s. 30–41.
• [22] Chang F.R. i wsp., Novel cytotoxic annonaceous acetogenins from Annona muricata, Journal of Natural Products, 2001, 64(7), s. 925–931.
• [23] Liaw C.C. i wsp., Montacin and cis-montacin, two new cytotoxic monotetrahydrofuran annonaceous acetogenins from Annona montana, Journal of Natural Products, 2004, 67(11), s. 1804–1808.
• [24] Wu Y.C., Cytotoxic mono tetrahydrofuran Annonaceous acetogenin montalicin anticancer, Bioorganic and Medicinal Chemistry, 2005, 13, s. 4767–4776.
• [25] Oberlies N.H., i wsp., Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells, Journal of Medicinal Chemistry, 1997, 40, s. 2102–2106.
• [26] De Sousa O.V. i wsp., Antinociceptive and Anti-Inflammatory Activities of the Ethanol Extract of Annona muricata L. Leaves in Animal Models, International Journal of Molecular Sciences, 2010, 11 (5), s. 2067–2078.
• [27] Roman G., Graviola can stimulate serotonin receptors, Current Opinion in Neurology, 1998, 11, s. 539–544.
• [28] Dvorkin-Camiel L., i wsp., Tropical American plants in the treatment of infectious diseases, Journal of Dietary Supplements, 2008, 5(4), s. 349–372.
• [29] Balch P., Prescription for Nutritional Healing, 2003, http://www.livestrong.com/article/412388-graviola-tree-supplements/#ixzz1mrsj6xcN
• [30] Neida S. i wsp., Characterization of the acai or manaca (Euterpe oleracea Mart.): a fruit of the Amazon, Archivos Latinoamerican Nutrition, 2007, 57(1), s. 94–98.
• [31] Oliveira de Souza M. i wsp., Diet supplementation with acai (Euterpe oleracea Mart.) pulp improves biomarkers of oxidative stress and the serum lipid profile in rats, Nutrition, 2010, (7–8), s. 804–810.
• [32] Spada P.D. i wsp., Frozen fruit pulp of Euterpe oleraceae Mart. (Acai) prevents hydrogen peroxide-induced damage in the cerebral cortex, cerebellum, and hippocampus of rats, Journal of Medicinal Food, 2009, 12(5), s. 1084–1088.
• [33] Porras-Reyes B.H. i wsp., Enhancement of wound healing by the alkaloid taspine defining mechanism of action, Proceeding of the Society and Experimental Biology and Medicine, 1993, 203(1), s. 18–25.
• [34] Rollinger J. M., Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana, Journal of Natural Products, 2006, 69(9), s. 1341–1346.
• [35] Dong Y. i wsp., Enhancement of wound healing by taspine and its effect on fibroblast, Zhong. Yao. Cai, 2005, 28(7), s. 579–82.
• [36] Dong Y. L. i wsp., Effect of taspine hydrochloride on skin wound healing in rats and its mechanism, Zhong. Xi. Yi. Jie. He. Xue. Bao, 2005, 3(5), s. 386–390.
• [37] Chen Z.P. i wsp., Studies on the anti-tumour, anti-bacterial, and wound-healing properties of dragon’s blood, Planta Medica, 1994, 60(6), s. 541–545.
• [38] Gurgel L.A. i wsp., In vitro antifungal activity of dragon’s blood from Croton urucurana against dermatophytes, Journal of Ethnopharmacology, 2005, 97(2), s. 409–412.
• [39] Frum Y. i wsp., In vitro 5-lipoxygenase and anti-oxidant activities of South African medicinal plants commonly used topically for skin diseases, Skin Pharmacology and Physiology, 2006, 19(6), s. 329–335.
• [40] Risco E. i wsp., Immunomodulatory activity and chemical characterisation of sangre de drago (dragon’s blood) from Croton lechleri, Planta Medica, 2003, 69(9), s. 785–794.
• [41] Jones K., Review of sangre de drago (Croton lechleri)-a South American tree sap in the treatment of diarrhea, inflammation, insect bites, viral infections, and wounds: traditional uses to clinical research, Journal Alternative and Complementary Medicine, 2003, 9(6), s. 877–896.
• [42] Tran C.D. i wsp., The role of Amazonian herbal medicine Sangre de Grado in Helicobacter pylori infection and its association with metallothionein expression, Helicobacter, 2006, 11(2), s. 134–135.
• [43] Lopes M.I. i wsp., Mutagenic and antioxidant activities of Croton lechleri sap in biological systems, Journal of Ethnopharmacology, 2004, 95(2-3), s. 437–445.
• [44] Desmarchelier C. i wsp., Effects of sangre de drago from Croton lechleri Muell.-Arg. on the production of active oxygen radicals, Journal of Ethnopharmacology, 1997, 58, s. 103–108.
• [45] Lemos T.L. i wsp., Quinones from plants of northeastern Brazil: structural diversity, chemical transformations, NMR data and biological activities, Natural Product Research, 2007, 21(6), s. 529–550.
• [46] Warashina T. i wsp., Constituents from the bark of Tabebuia impetiginosa, Phytochemistry, 2004, 65, s. 2003–2011.
• [47] Warashina T. i wsp., Further constituents from the bark of Tabebuia impetiginosa, Phytochemistry, 2005, 66, s. 589–597.
• [48] Castellanos J.R.G. i wsp., Red Lapacho (Tabebuia impetiginosa) – A global ethnopharmacological commodity? Journal of Ethnopharmacology, 2009, 121, s. 1–13.
• [49] Mukherjee B. i wsp., Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree, International Journal of Molecular Medicine, 2009, 24(2), s. 253–260.
• [50] Moon D.O. i wsp., Beta-lapachone (LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of telomerase activity by LAPA, Journal of Medicinal Food, 2010, 13(3), s. 481–488.
• [51] Byeon S.E. i wsp., In vitro and in vivo anti-inflammatory effects of taheebo, a water extract from the inner bark of Tabebuia avellanedae, Journal of Ethnopharmacology, 2008, 119(1), s. 145–152.
• [52] Fu S.C. i wsp., β-lapachone accelerates the recovery of burn-wound skin, Histology and Histopathology, 2011, 26(7), s. 905–914.
• [53] Kiage-Mokua B.N. i wsp., Lapacho Tea (Tabebuia impetiginosa) Extract inhibits pancreatic lipase and delays postprandial triglyceride increase in rats, Phytotherapy Research, 2012, 26(12), s. 21878–21883.
• [54] Lima N.M.F. i wsp., Antileishmanial activity of lapachol analogues, Memorias do Instituto Oswaldo Cruz, 2004, 99, s. 757–761.
• [55] Tupper K.W., The globalization of ayahuasca: Harm reduction or benefit maximization?, International Journal of Drug Policy, 2008, 19(4), s. 297–303.
• [56] McIlhenny E.H. i wsp., Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography – electrospray ionization-tandem mass spectrometry, Journal of Chromatography A, 2009, 1216, s. 8960–8968.
• [57] Labate B.C. i wsp., The expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS „Psychodelic Science in the 21st Century” conference, International Journal of Drug Policy, 2011, 22, s. 174–178.